Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding ...
Q2 2026
May 11, 2026
Q1 2026
Mar 5, 2026
FY 2025
Nov 12, 2025
Q4 2025
Q3 2025
Aug 12, 2025